Ionis Pharmaceuticals shares surged 42% after reporting positive results from two pivotal Phase III trials evaluating olezarsen for severe hypertriglyceridemia. The antisense oligonucleotide surpassed primary endpoints, showing up to 72% placebo-adjusted triglyceride reduction and an 85% decrease in acute pancreatitis events at six months. These highly significant findings position olezarsen as a potential blockbuster for a population with few effective treatments. Ionis plans to file a supplemental NDA by year-end with a commercial launch slated for 2026, underscoring its strategy to expand antisense therapeutics in metabolic disease.